73 results about "Myocardial infarction syndrome" patented technology

Methods of determining the effectiveness of anti-inflammatory compounds in reducing incidence of myocardial infarction are described. Methods of prophylaxis against myocardial infarctions which exhibit CK-MB levels greater than about 50 nano-grams / ml in a subject are also provided.

The invention relates to a myocardial infarction and heart failure magnetic microparticle microfluidic biochip, which belongs to the technical field of POCT detection. The myocardial infraction and heart failure magnetic microparticle microfluidic biochip comprises a PCB board, wherein the PCB board is provided with a microflow passage, a biosensor is arranged in the microflow passage, the biosensor consists of a wafer platform and a point sample antibody covered on the wafer platform, the point sample antibody can form an immune complex with a magnetic bead coupling antibody and a marker protein, and the concentration of the marker protein can be judged by determining a magnetic resistance signal on the wafer platform. In the technical scheme, the magnetic bead has a larger specific surface area, and by combining more antibodies, the detection sensitivity is improved, and the specificity is higher than that of a fourth-generation chemical luminescent method. The invention also provides a detection method using the biochip. The heart markers such as myocardial infarction and heart failure can be simultaneously and quantitatively detected, the detection lower limit can be improved,and the leakage detection and false negative phenomenon can be effectively avoided.

The invention discloses a screening method for lncRNA relevant to myocardial ischemia reperfusion. The method comprises the following steps: constructing an extracorporeal myocardial cell anoxia reaeration model, and screening lncRNA with differential expression in a myocardial cell anoxia reaeration process by using a Rat LncRNA Array v2.0 chip; constructing an extracorporeal myocardial cell anoxia reaeration model and a langendorff isolated heart ischemia reperfusion model, and verifying the result of the chip by using a real-time quantitative PCR. Interference lncRNA is used, so that expression is reduced, an autophagia level in cardiac muscle cells are adjusted and controlled, and the purpose of protecting myocardial anoxia reaeration damage is realized; therefore, the invention provides the method of protecting the cardiac muscle cell anoxia reaeration damage of the cardiac muscle cells by adjusting and controlling the lncRNA, and has an important significance for further researching lncRNA relevant to the myocardial ischemia reperfusion in the aspect of predicting, and preventing and treating miocardial infarction.

It is intended to provide a novel polypeptide having an activity of growing vascular endothelial cells, an activity of promoting transcription form c-fos promoter, an activity of promoting transciption from VEGF promoter and / or an angiogenic activity; a polynucleotide encoding this polypeptide; the above polypeptide and / or a pharmaceutical composition containing the polypeptide for treating a disease selected from the group consisting of obstructive arteriosclerosis, Buerger's disease, peripheral vascular disorder, angina, myocardial infraction, brain infarction, ischemic heart disease and ischemic brain disease; a method of treating these diseases; and an antibacterial composition. The above problems can be solved by isolating a novel peptide having the above-described activities and a nucleotide encoding this peptide.

The invention relates to application of E1A-simulated gene cellular repressor (CREG) protein, in particular to application of CREG protein or active fragment thereof in preparation of drug used for preventing and / or treating acute myocardial infarction, heart failure after acute myocardial infarction and / or ventricular remodeling after the same. The invention further relates to application of recombinant vector or recombinant cell expressing the CREG protein or the active fragment thereof in preparation of the drug used for preventing and / or treating acute myocardial infarction, heart failure after acute myocardial infarction and / or ventricular remodeling after the same.

The present invention relates to a stable pharmaceutical composition comprising an ACE inhibitor or a pharmaceutically acceptable salt or derivative thereof. In particular, the invention relates to a pharmaceutical composition, which comprises an ACE inhibitor, or a pharmaceutically acceptable salt or a derivative thereof, and a C16-C28 glyceride. ACE inhibitors useful in the present invention are susceptible to heat and / or mechanical stress-induced degradation. Preferred ACE inhibitors are ramipril, trandolapril, quinapril and pharmaceutically acceptable salts and derivatives thereof. The composition of the present invention may be for use as a medicament for the treatment or prevention of a cardiovascular disease, a coronary heart disease, a cerebrovascular disease, a peripheral vascular disease, arrhythmia, hypertension, cardiac failure, cardiovascular death, myocardial infraction, stroke or angina. The present invention further relates to a method of preparing the pharmaceutical composition of the present invention. The present invention also relates to a method of providing a stable pharmaceutical composition comprising an ACE inhibitor, or a pharmaceutically acceptable salt or derivative thereof, by incorporating a C16-C28 glyceride into the composition. The present invention further relates to a use of C16-C28 glyceride to provide a stable pharmaceutical composition comprising an ACE inhibitor or a pharmaceutically acceptable salt or derivative thereof.

The invention provides a drug for reducing myocardial damage caused by ischemia reperfusion or a drug for treating cardiac ischemic diseases. The drug is prepared by taking a DNA tetrahedron as an active ingredient and adding pharmaceutically acceptable auxiliary materials, wherein the DNA tetrahedron is a tetrahedral structure formed by hybridization of four DNA single strands according to the same amount of substance. The drug has good protection and repair functions on myocardium, inhibits apoptosis of myocardial cells, and has the good curative effect on myocardial infarction and other ischemic diseases.

The present invention relates to non-invasive methods for early diagnosis and / or differential diagnosis of acute myocardial infarction in a blood sample of a subject. Further, the present invention relates to polynucleotides or sets of polynucleotides for detecting miRNAs or sets of miRNAs for early diagnosis and / or differential diagnosis of acute myocardial infarction in a blood sample of a subject.

The present invention describes novel nitrosated and / or nitrosylated phosphodiesterase inhibitors, and novel compositions containing at least one nitrosated and / or nitrosylated phosphodiesterase inhibitor, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or one or more vasoactive agents. The present invention also provides novel compositions containing at least one phosphodiesterase inhibitor, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing diseases induced by the increased metabolism of cyclic guanosine 3′,5′-monophosphate (cGMP), such as hypertension, pulmonary hypertension, congestive heart failure, renal failure, myocardial infraction, stable, unstable and variant (Prinzmetal) angina, atherosclerosis, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, stroke, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, dementia, immunodeficiency, premature labor, dysmenorrhoea, benign prostatic hyperplasis (BPH), bladder outlet obstruction, incontinence, conditions of reduced blood vessel patency, e.g., postpercutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, allergic rhinitis, glucoma, and diseases characterized by disorders of gut motility, e.g., irritable bowel syndrome (IBS).

The invention relates to the field of medical diagnosis and in particular to a kit for predicting the risk of acute myocardial infarction. The kit comprises detection reagents of microRNA-22-5p and / ormicroRNA-375. The invention further relates to application of microRNA-22-5p and / or microRNA-375 as molecular markers in preparing diagnosis agents for predicting the risk of acute myocardial infarction. The kit provided by the invention has very good diagnosis and prediction effects on AMI (Acute Myocardial Infarction) and is capable of predicting the disease risk of AMI, instructing preventionand treatment on AMI and alleviating threats of AMI.

The invention relates to application of miR-1912 and a target gene thereof in diagnosis and treatment of myocardial infarction. According to the application, expression data of miRNA and mRNA of myocardial infarction and healthy control are obtained by second-generation sequencing; meanwhile, bioinformatics analysis verification and molecular validation are performed by combining the miRNA and mRNA data related to the myocardial infarction in a GEO database; results show that the miR-1912 and the target gene ZDHHC18 thereof are closely related to the myocardial infarction, can be used for clinical diagnosis, prevention and detection of the myocardial infarction, and lay a foundation for the development of clinically relevant diagnostic reagents, chips or the like.

Provided is a method of distinguishing among Stanford type A acute aortic dissection, Stanford type B acute aortic dissection, and acute myocardial infarction, which are mutually similar in terms of clinical symptoms, and a kit for the distinguishment. Specifically, provided is a method of distinguishing among Stanford type A acute aortic dissection, Stanford type B acute aortic dissection, and acute myocardial infarction, which comprises detecting both D-dimer and H-FABP in blood separated from a person suspected of having acute aortic dissection and suspected of having acute myocardial infarction, and establishing the diagnosis on the basis of the concentrations detected, and a kit for the distinguishment.

The invention provides an application of an miRNA marker for diagnosing acute myocardial infarction, a product using the miRNA marker and a detection method, and relates to the technical field of medical molecular biology. The miR-26a-1, miR-146a or miR-199a-1 can be singly or jointly applied as markers for assisting early diagnosis of myocardial infarction, and the plasma level of the miR-26a-1,miR-146a or miR-199a-1 is obviously increased in the early stage of occurrence of myocardial infarction; and the miRNA in the blood of patients with acute myocardial infarction is released into the blood earlier than intracellular protein markers, so that the detection of the plasma level of the miRNA can be used as a biomarker for assisting early diagnosis of acute myocardial infarction. The three miRNA markers can be used as markers for early diagnosis of heart diseases, and thus the sensitivity and specificity of disease diagnosis are greatly improved.

The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to some other surface by catalyzing antithrombin; and (2) inhibiting thrombin generation by catalyzing factor Xa inactivation by antithrombin III (ATIII). The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infraction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.

The invention discloses an application of an polypeptide in medicines for preventing or treating myocardial ischemia-reperfusion injury related diseases, and belongs to the field of biomedicines. The amino acid sequence of the polypeptide is SEQ ID NO.1 or SEQ ID NO.2. The polypeptide can substantially reduce the myocardial infarction area in myocardial ischemia-reperfusion injury, can be used as a medicine for preventing or treating the myocardial ischemia-reperfusion injury related diseases, and has clinic application values.

The invention discloses a metabolic marker for diagnosing and distinguishing unstable angina pectoris and acute myocardial infarction, comprising one or more of N-phenylalanyl-L-glutamine, sphinganine, arachidonic acid, eicosatrienoic acid, glycocholic acid, lysophosphatidylcholine (14:0), tryptophan-arginine-leucine tripeptide, lysophosphatidylcholine (18:2), and lysophosphatidylcholine (20:3). In the single use of diagnosing and distinguishing patients with acute myocardial infarction and patients with unstable angina pectoris, each ROC (receiver operating characteristic) AUC (area under the curve) is greater than 0.7, and clinical diagnostic significance is provided; in the joint use for diagnosis, AUC further increases as a joint quantity increases, a highest AUC up to 0.991 is obtained in a case of nine members jointed, and sensitivity and specificity are respectively 99.2% and 98.9% under an optimal cutoff value. The metabolic marker can accurately diagnose and distinguish unstable angina pectoris and acute myocardial infarction, with high accuracy and high sensitivity and specificity.

The invention discloses application of EMD638683 in protection of the heart suffering from acute myocardial infarction. The invention provides application of EMD638683 in preparation of products having the following functions: 1) prevention and / or treatment of myocardial infarction of animals; 2) prevention and / or treatment of heart failure caused by myocardial infarction of animals; and 3) inhibition of the expression of SGK1 protein in cardiac muscle tissue after myocardial infarction of animals. Experimental results of the invention prove that EMD638683 has treatment effect on mice with myocardial infarction, and experimental data is provided for clinical application of EMD638683 in treatment of myocardial infarction. The EMD638683 is of important theoretical significance to research on and development of medicines used for preventing and treating heart failure caused by myocardial infarction and has good application prospects.

The invention discloses an ING1 gene which can serve as a diagnosis tool of myocardial infarction. High-throughput sequencing and QPCR (quantitative polymerase chain reaction) research know that the content of the ING1 gene in blood of a myocardial infarction patient remarkably rises as compared with normal people, western blot experiment results show that the content of ING protein in blood of the myocardial infarction patient remarkably rises as compared with normal people, so that the ING1 gene and the ING protein can serve as molecular markers of diagnosis of the myocardial infarction. Thecontent of the gene or the protein in the blood represents the myocardial infarction, so that a representing method has the advantages that tissue sampling detection is avoided, subject pain is relieved, the representing method can be used for screening of healthy people, and the myocardial infarction is effectively prevented.

The invention belongs to the field of biomedicine, and provides an miRNA-21a inhibitor. The nucleotide sequence of the miRNA-21a inhibitor is shown as SEQ ID NO:1. The invention further provides application of the miRNA-21a inhibitor in preparing medicine for inhibiting myocardial infarction early stage inflammation or delaying the development of myocardial infarction early stage inflammation. The expression of miRNA-21a in the early stage of myocardial infarction is significantly increased, and the miRNA-21a inhibitor can inhibit myocardial infarction and inflammation increase caused by related factors and perform the anti-inflammation function for myocardial infarction in the early stage when applied internally or externally. The miRNA-21a inhibitor can be applied to preparing medicine for inhibiting myocardial infarction early stage inflammation or delaying the development of myocardial infarction.

The invention discloses a diagnostic marker of inferior myocardial infarction and / or anterior myocardial infarction. The diagnostic standard substance is a lysophosphatidylcholine substance; a high performance liquid chromatography-mass spectrometry detects that the contents of lysoPC (14:0), lysoPC (15:0), lysoPC (17:0) and lysoPC (18:0) in blood of patients suffering from the myocardial infarction are obviously lower than those in blood of normal people, and the contents of the lysoPC (14:0), the lysoPC (15:0), the lysoPC (17:0) and the lysoPC (18:0) in blood of patients suffering from the inferior myocardial infarction and the anterior myocardial infarction also have significant differences. According to research results, the invention develops a product for diagnosing the myocardial infarction, and the diagnostic product has high sensitivity and strong specificity and can be used in clinical popularization.

The invention relates to application of a lecithin superoxide dismutase composite in preparation of medicines for treating and / or preventing cardiac ischemic injury, wherein the lecithin superoxide dismutase composite is dipolymer combined with different molecule numbers of lecithin, and the concrete method comprises the following steps of: establishing a cardiac ischemic injury animal model; preparing a cardiac injury induced model for verifying a function of the cardiac ischemic injury animal model in cardiac protection treatment under the asepsis condition, spreading sacculus, blocking the sacculus for a long time and loosening the sacculus through injecting a contrast agent into the small pig coronary artery left anterior descending branch balloon implant so as to respectively establish a myocardial infarction model and a myocardial injury model through blood liquid infusion; and injecting the lecithin superoxide dismutase composite containing different molecule numbers of lecithin into the animal model so as to observe a new function of treating cardiac injury.

The invention discloses application of MSN / miRNA hydrogel in preparing medicine for treating myocardial infarction. The MSN is porous mesoporous silicon nanospheres, and the miRNA is miR-21. The hydrogel has the following advantages that 1, through modification of amine functional groups on the surfaces of the MSN nanospheres, a Schiff base reaction with aldehyde groups in hydrocolloid is conducted, thereby achieving precise treatment by using a weakly acidic environment of the myocardial infarction; 2, the aldehyde groups in the hydrocolloid can tightly adhere to cardiac muscle tissue in a treatment area, thereby achieving a stable therapeutic effect; 3, the MSN nanospheres regulate the immune response, thereby improving the reconstruction function of the cardiac muscle tissue; 4, miR-21micromolecules are delivered, thereby promoting local vascularization in a myocardial infarction area, thereby reducing the myocardial infarction size. Therefore, the hydrogel has important application value in treating the myocardial infarction.

The invention discloses application of a Vinexin-beta gene in coronary atherosclerotic heart disease, and belongs to the field of functions and application of the gene. According to the invention, Vinexin-beta knockout mouse and heart specificity Vinexin-beta transgenic mouse serve as experimental subjects and mouse heart ramus descendens anterior arteriae coronariae sinistrae (LAD) is blocked to form a myocardial infarction model, and a result shows that, compared with a WT control mouse, the Vinexin-beta knockout mouse is significantly inhibited in myocardial infarction proportion, myocardial hypertrophy and fibrosis degree and is remarkably better in heart functions, while the heart specificity Vinexin-beta transgenic mouse is obviously more serious in myocardial infarction proportion, myocardial hypertrophy and fibrosis degree and is remarkably worse in the heart functions, showing that the Vinexin-beta gene can promote and enhance occurrence and development of the coronary atherosclerotic heart disease. Therefore, the Vinexin-beta gene can serve as a drug target to screen medicines for treating the coronary atherosclerotic heart disease, and a Vinexin-beta inhibitor can be used for preparing a medicine for treating the coronary atherosclerotic heart disease.

The invention provides application of MED6 genes serving as an acute myocardial infarction risk prediction marker. The MED6 genes or gene expression products are taken as a novel acute myocardial infarction risk prediction and diagnoses and treatment target. The MED6 genes and expression products thereof are used for preparing acute myocardial infarction risk prediction markers and diagnoses preparations and have important clinical application significance and development values.

The invention relates to an application of a miRNA repressor in preparing a drug for preventing and controlling myocardial infarction. The invention firstly utilizes a miRNA-9 repressor to treat myocardial infarction. The embodiment has the following extraordinary technical effects: the direct injection of the miR-9 repressor through cardiac muscle is capable of obviously reducing the expression of heart miR-9, the miR-9 repressor injected into the peripheral area of acute myocardial infarction is capable of effectively improving the heart function after myocardial infarction and reducing themyocardial infarction area, inflammation level and ROS accumulation degree in the peripheral area of acute myocardial infarction and the miRNA repressor can be used for preventing and treating the myocardial infarction.

The invention discloses application of RAE 1 gene or protein as a biomarker for diagnosing myocardial infarction. The content of an RAE1 gene in the blood of a myocardial infarction patient has an obvious difference from normal people, and the myocardial infarction patient and normal crowds can be distinguished according to the difference. The invention also discloses a diagnosis product for the myocardial infarction, and the diagnosis product can be used for realizing a myocardial infarction diagnosis purpose through the detection of the RAE1 gene in the blood.

The invention relates to an application of an early found self-assembled micro-molecular puerarin hydrogel in myocardium repairing after myocardial infarction. An in vitro experiment part according to the invention proves that the hydrogel has excellent cytocompatibility and anti-peroxidation capacity; an in vivo experiment part proves that the puerarin hydrogel can be used for repairing the myocardial infarction tissues in the manner of injection, can carry the mesenchymal stem cells and can promote the effect of repairing myocardial infarction through transplanted cells; a research result proves that the hydrogel has an excellent application prospect in myocardial infarction treatment.

The invention relates to application of serum S100a8 / 9 complex level in diagnosis and prognosis of acute myocardial infarction. The prognosis is characterized by predicting conditions of prognosis ofAMI patients after percutanecus coronary intervention and distinguishing the patients into a group with high risk of postoperative adverse events and a group with low risk of postoperative adverse events; the adverse events comprise and are not limited to death and acute heart failure.